864 related articles for article (PubMed ID: 23890062)
1. Dendritic-cell-based therapeutic cancer vaccines.
Palucka K; Banchereau J
Immunity; 2013 Jul; 39(1):38-48. PubMed ID: 23890062
[TBL] [Abstract][Full Text] [Related]
2. Engineering better immunotherapies via RNA interference.
Sioud M
Hum Vaccin Immunother; 2014; 10(11):3165-74. PubMed ID: 25483669
[TBL] [Abstract][Full Text] [Related]
3. Current status and future applications of cellular therapies for cancer.
Copier J; Bodman-Smith M; Dalgleish A
Immunotherapy; 2011 Apr; 3(4):507-16. PubMed ID: 21463192
[TBL] [Abstract][Full Text] [Related]
4. Current developments of immunotherapy in the clinic.
Antonia S; Mulé JJ; Weber JS
Curr Opin Immunol; 2004 Apr; 16(2):130-6. PubMed ID: 15023403
[TBL] [Abstract][Full Text] [Related]
5. Dendritic cells: a journey from laboratory to clinic.
Cerundolo V; Hermans IF; Salio M
Nat Immunol; 2004 Jan; 5(1):7-10. PubMed ID: 14699398
[No Abstract] [Full Text] [Related]
6. Turbocharging vaccines: emerging adjuvants for dendritic cell based therapeutic cancer vaccines.
Saxena M; Bhardwaj N
Curr Opin Immunol; 2017 Aug; 47():35-43. PubMed ID: 28732279
[TBL] [Abstract][Full Text] [Related]
7. Phenotypic profile of dendritic and T cells in the lymph node of Balb/C mice with breast cancer submitted to dendritic cells immunotherapy.
da Cunha A; Antoniazi Michelin M; Cândido Murta EF
Immunol Lett; 2016 Sep; 177():25-37. PubMed ID: 27423825
[TBL] [Abstract][Full Text] [Related]
8. Dendritic Cells Therapy with Cytokine-Induced Killer Cells and Activated Cytotoxic T Cells Attenuated Th2 Bias Immune Response.
Li C; Zhu D; Zhao Y; Guo Q; Sun W; Li L; Gao D; Zhao P
Immunol Invest; 2020 Jul; 49(5):522-534. PubMed ID: 31793363
[TBL] [Abstract][Full Text] [Related]
9. Dendritic cell-based combined immunotherapy with autologous tumor-pulsed dendritic cell vaccine and activated T cells for cancer patients: rationale, current progress, and perspectives.
Morisaki T; Matsumoto K; Onishi H; Kuroki H; Baba E; Tasaki A; Kubo M; Nakamura M; Inaba S; Yamaguchi K; Tanaka M; Katano M
Hum Cell; 2003 Dec; 16(4):175-82. PubMed ID: 15147037
[TBL] [Abstract][Full Text] [Related]
10. Unleashing the Therapeutic Potential of Dendritic and T Cell Therapies Using RNA Interference.
Sioud M
Methods Mol Biol; 2020; 2115():259-280. PubMed ID: 32006406
[TBL] [Abstract][Full Text] [Related]
11. Dendritic Cells and Their Role in Immunotherapy.
Gardner A; de Mingo Pulido Á; Ruffell B
Front Immunol; 2020; 11():924. PubMed ID: 32508825
[TBL] [Abstract][Full Text] [Related]
12. Dendritic cells: are they clinically relevant?
Palucka K; Ueno H; Roberts L; Fay J; Banchereau J
Cancer J; 2010; 16(4):318-24. PubMed ID: 20693842
[TBL] [Abstract][Full Text] [Related]
13. Cellular immunotherapy of cancer: an overview and future directions.
Tao Z; Li S; Ichim TE; Yang J; Riordan N; Yenugonda V; Babic I; Kesari S
Immunotherapy; 2017 Jun; 9(7):589-606. PubMed ID: 28595516
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy with dendritic cells for cancer.
Ballestrero A; Boy D; Moran E; Cirmena G; Brossart P; Nencioni A
Adv Drug Deliv Rev; 2008 Jan; 60(2):173-83. PubMed ID: 17977615
[TBL] [Abstract][Full Text] [Related]
15. Nanomedicine for improvement of dendritic cell-based cancer immunotherapy.
Hashemi V; Farhadi S; Ghasemi Chaleshtari M; Seashore-Ludlow B; Masjedi A; Hojjat-Farsangi M; Namdar A; Ajjoolabady A; Mohammadi H; Ghalamfarsa G; Jadidi-Niaragh F
Int Immunopharmacol; 2020 Jun; 83():106446. PubMed ID: 32244048
[TBL] [Abstract][Full Text] [Related]
16. Integrin β4-Targeted Cancer Immunotherapies Inhibit Tumor Growth and Decrease Metastasis.
Ruan S; Lin M; Zhu Y; Lum L; Thakur A; Jin R; Shao W; Zhang Y; Hu Y; Huang S; Hurt EM; Chang AE; Wicha MS; Li Q
Cancer Res; 2020 Feb; 80(4):771-783. PubMed ID: 31843981
[TBL] [Abstract][Full Text] [Related]
17. A review of dendritic cell therapy for cancer: progress and challenges.
Mantia-Smaldone GM; Chu CS
BioDrugs; 2013 Oct; 27(5):453-68. PubMed ID: 23592406
[TBL] [Abstract][Full Text] [Related]
18. Effective cancer immunotherapy by natural mouse conventional type-1 dendritic cells bearing dead tumor antigen.
Wculek SK; Amores-Iniesta J; Conde-Garrosa R; Khouili SC; Melero I; Sancho D
J Immunother Cancer; 2019 Apr; 7(1):100. PubMed ID: 30961656
[TBL] [Abstract][Full Text] [Related]
19. Dendritic cells in cancer immunotherapy. 10 January 2005, London, UK.
George AJ
IDrugs; 2005 Feb; 8(2):104-6. PubMed ID: 15696407
[No Abstract] [Full Text] [Related]
20. Val-boroPro accelerates T cell priming via modulation of dendritic cell trafficking resulting in complete regression of established murine tumors.
Walsh MP; Duncan B; Larabee S; Krauss A; Davis JP; Cui Y; Kim SY; Guimond M; Bachovchin W; Fry TJ
PLoS One; 2013; 8(3):e58860. PubMed ID: 23554941
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
